CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting \>24 hours or results in death (in \<24 hours).

To assess the effect of an 11 day course of once daily darapladib EC 160 mg on the number and phenotype (M1/M2 polarization) of macrophages isolated from blisters on subjects with type 2 diabetes mellitus (blisters induced by exposure to cantharidin for 48 hours). Biomarkers may include, but not be limited to: Cluster of differentiation (CD)11b, CD14, CD16, CD33, CD40, CD64, CD68, CD86, CD163, CD206, C-C chemokine receptor type 2 (CCR2), CX3 chemokine receptor 1 (CX3CR1)

An AE is any untoward medical occurrence in a patient or clinical investigation Subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

12-lead ECGs will be obtained at designated timepoint during the study, using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.

Systolic and diastolic blood pressure and pulse rate

Hematology, clinical chemistry, urinalysis and additional parameters to be tested

Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration

Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time

Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time

Accumulation ratios Cmax accumulation ratio

Accumulation ratios Cmax accumulation ratio

The physical examination will include assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen).

The effects of repeat oral dosing of darapladib (160mg enteric coated \[EC\] tablet once daily \[QD\]) on the pharmacokinetic parameters - Cmax and AUC(0-infinity\[inf\]) of a single oral dose of midazolam (5 mg) will be evaluated

The area under the concentrations-time curve (AUC0-24) from the time of administration of darapladib up to 24 h after administration.

The maximum concentration (Cmax) was obtained directly from the measured concentration-time curves.

To evaluate the single dose PK of Rosuvastatin, area under the concentration-time curve from time zero extrapolated to infinite time (AUC \[0-infinity\]) or area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC \[0-t\]) will be assessed.

To evaluate the single dose PK of Rosuvastatin, maximum observed concentration (Cmax) will be assessed.

To evaluate the single dose PK of Rosuvastatin, time of occurrence of Cmax (Tmax), and terminal phase half-life (T1/2) will be assessed.

The PK parameter area under the concentration-time curve over the dosing interval (AUC (0-τ)) will be derived from the plasma concentration-time data.

The PK parameter maximum observed concentration (Cmax) will be derived from the plasma concentration-time data.